Endava (DAVA) CTO details share, option and RSU holdings in Form 3

Rhea-AI Filing Summary

Endava plc Chief Technology Officer Matthew Cloke has filed an initial statement of holdings. He reports direct ownership of 4,342 Class A Ordinary Shares. He also holds share options over 155, 218 and 315 Class A Ordinary Shares with exercise prices of $69.47, $49.34 and $21.72 per share, expiring between December 2032 and April 2035. In addition, he holds restricted share units over 5,538 and 21,152 Class A Ordinary Shares that vest in scheduled annual installments between October 2026 and October 2028.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cloke Matthew

(Last) (First) (Middle)

C/O ENDAVA PLC

125 OLD BROAD STREET

(Street)

LONDON EC2N 1AR

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Endava plc [ DAVA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Class A Ordinary Shares(1)	4,342	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(2)	12/01/2032	Class A Ordinary Shares	155	$69.47	D
Share Option (right to buy)	(3)	12/01/2033	Class A Ordinary Shares	218	$49.34	D
Share Option (right to buy)	(4)	04/01/2035	Class A Ordinary Shares	315	$21.72	D
Restricted Share Units	(5)	(5)	Class A Ordinary Shares	5,538	(6)	D
Restricted Share Units	(7)	(7)	Class A Ordinary Shares	21,152	(6)	D

Explanation of Responses:

1. The Class A Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one ordinary share.

2. Fully vested and exercisable.

3. This option will vest on December 1, 2026.

4. This option will vest on April 1, 2028.

5. The restricted share units ("RSUs") vest in 2 equal annual installments on October 31, 2026 and October 31, 2027.

6. Each RSU represents a contingent right to receive one Issuer Class A Ordinary Share or, at the option of the Issuer, cash.

7. The RSUs vest in 3 equal annual installments on October 31, 2026, October 31, 2027 and October 31, 2028.

	/s/ Rohit Bhoothalingam, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Endava (DAVA) CTO Matthew Cloke report in this Form 3 filing?

Matthew Cloke reports his existing ownership in Endava. He directly holds 4,342 Class A Ordinary Shares, several option awards, and restricted share units that convert into Class A Ordinary Shares according to specified exercise prices and vesting schedules.

How many Endava (DAVA) Class A Ordinary Shares does the CTO directly own?

The CTO directly owns 4,342 Class A Ordinary Shares of Endava. This direct position is separate from his options and restricted share units, which represent additional contingent or exercisable rights to receive more Class A Ordinary Shares in the future.

What share options are reported by Endava (DAVA) CTO Matthew Cloke?

He reports three share option grants over 155, 218 and 315 Class A Ordinary Shares. The exercise prices are $69.47, $49.34 and $21.72, with expiration dates in December 2032, December 2033 and April 2035, respectively, all held directly.

What restricted share units (RSUs) does the Endava (DAVA) CTO hold?

He holds RSUs over 5,538 and 21,152 Class A Ordinary Shares. One grant vests in two equal annual installments on October 31, 2026 and 2027, while the other vests in three equal annual installments from October 31, 2026 through October 31, 2028.

How do Endava (DAVA) RSUs for the CTO settle when they vest?

Each RSU represents a contingent right to receive one Endava Class A Ordinary Share or, at Endava’s option, cash. Settlement occurs as the RSUs vest on the specified October 31 vesting dates across 2026, 2027 and 2028.

Are any of the Endava (DAVA) CTO’s options already vested and exercisable?

One option grant is described as fully vested and exercisable. Other options have future vesting dates, including one that will vest on December 1, 2026 and another scheduled to vest on April 1, 2028, subject to their terms.